

Please amend the above-referenced application as follows:

In the Specification:

Please amend the disclosure on page 1 to read:

C' This application is a continuation application of serial no. 08/599,226, filed on February 9, 1996, issued as Patent No. 6,090,382. The contents of all of the aforementioned application(s) are hereby incorporated by reference.

In the Claims:

Please cancel claims 72, 74, 75, and 82 without prejudice.

Please amend the claims as follows (for convenience all of the claims, whether amended or not, are presented below):

C2 65. A method for inhibiting human TNF α activity comprising contacting human TNF α with an antibody such that human TNF α activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF α with a K_d of 1×10^{-8} M or less and a K_{off} rate constant of $1 \times 10^{-3} \text{ s}^{-1}$ or less, both determined by surface plasmon resonance, and neutralizes human TNF α cytotoxicity in a standard *in vitro* L929 assay with an IC_{50} of 1×10^{-7} M or less.

66. A method for inhibiting human TNF α activity comprising contacting human TNF α with an antibody such that human TNF α activity is inhibited, wherein the antibody is an isolated human antibody, or antigen-binding portion thereof, with the following characteristics:

a) dissociates from human TNF α with a K_{off} rate constant of $1 \times 10^{-3} \text{ s}^{-1}$ or less, as determined by surface plasmon resonance;

62

C